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OBJECTIVES This study was designed to investigate whether or not combination aspirin-clopidogrel
therapy would reduce markers of thrombogenesis and platelet activation in atrial fibrillation
(AF), in a manner similar to warfarin.
BACKGROUND Dose-adjusted warfarin is beneficial as thromboprophylaxis in AF, but potentially serious side
effects and regular monitoring leave room for alternative therapies.
METHODS We randomized 70 patients with nonvalvular AF who were not on any antithrombotic
therapy to either dose-adjusted warfarin (international normalized ratio 2 to 3) (Group I) or
combination therapy with aspirin 75 mg and clopidogrel 75 mg (Group II). Plasma indices
of thrombogenesis (fibrin D-dimer, prothrombin fragment 12) and platelet activation
(beta-thromboglobulin [TG] and soluble P-selectin) were quantified, along with platelet
aggregation responses to standard agonists, at baseline (pretreatment) and at six weeks
posttreatment.
RESULTS Pretreatment levels of fibrin D-dimer (p 0.001), beta-TG (p 0.01) and soluble P-selectin
(p 0.03) were raised in patients with AF, whereas plasma prothrombin fragment 12 levels
and platelet aggregation were not significantly different compared with controls. Dose-
adjusted warfarin reduced plasma levels of fibrin D-dimer, prothrombin fragment 12 and
beta-thromboglobulin levels at six weeks (all p  0.001), enhanced plasma levels of soluble
P-selectin (p  0.001) and had no significant effect on platelet aggregation. Aspirin-
clopidogrel combination therapy made no difference to the plasma markers of thrombogenesis
or platelet activation (all p  NS), but the platelet aggregation responses to adenosine
diphosphate (p  0.001) and epinephrine (p  0.02) were decreased.
CONCLUSIONS Aspirin-clopidogrel combination therapy failed to reduce plasma indices of thrombogenesis
and platelet activation in AF, although some aspects of ex vivo platelet aggregation were
altered. Anticoagulation with warfarin may be superior to combination aspirin-clopidogrel
therapy as thromboprophylaxis in AF. (J Am Coll Cardiol 2002;40:484–90) © 2002 by the
American College of Cardiology Foundation
There is increasing evidence that the increased risk of stroke
and thromboembolism in atrial fibrillation (AF) is facili-
tated by increased thrombogenesis, with relative intraatrial
stasis, changes in the left atrial wall and a prothrombotic or
hypercoagulable state in AF, leading to the fulfillment of
Virchow’s triad (1). A prothrombotic or hypercoagulable
state in AF is evident by the presence of abnormalities of
hemostasis that are independent of underlying structural
heart disease or etiology (1).
Clinical trials have established the role for adjusted-dose
warfarin (target international normalized ratio [INR] 2 to 3)
as thromboprophylaxis in AF, whereas the benefits of
antiplatelet therapy such as aspirin are inconsistent (2).
However, warfarin poses a significant threat of bleeding and
warrants regular anticoagulation monitoring, contributing
to a general reluctance to commence anticoagulation ther-
apy and to noncompliance among patients (3,4). Efforts
have thus been made to find a viable alternative to warfarin
for thromboprophylaxis in AF. Nevertheless, trials with low
intensity or fixed-minidose warfarin, or a combination of
fixed-dose warfarin with aspirin, have been disappointing
(5).
The utility of measuring various markers of hypercoagu-
lability to indicate the effectiveness of antithrombotic ther-
apy has been demonstrated by randomized trials where fixed
low-dose (1 mg) warfarin, warfarin-aspirin combination
therapy or aspirin 300 mg did not significantly reduce
elevated indices of thrombogenesis and platelet activation in
nonvalvular AF, although conventional warfarin therapy did
normalize levels of these markers (6,7). These observations
were consistent with the beneficial effect of full-dose war-
farin in preventing stroke and thromboembolism in patients
with AF in clinical trials, and suggested that fixed low-dose
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(1 mg) warfarin, warfarin-aspirin combination therapy or
aspirin 300 mg may not exert similar beneficial effects in
reducing thrombogenesis, in keeping with the subsequent
publication of the results from their respective clinical trials
(5).
The role of platelet activation in AF needs to be better
defined (8) and an investigation into the influence of
combination antiplatelet therapy in AF is warranted. Aspi-
rin exerts its antithrombotic effect by inhibiting the synthe-
sis of thromboxane A2, which potentiates platelet aggrega-
tion and the release of granule contents (9–11). However,
aspirin is not a universally effective antithrombotic agent, as
platelet activation could still occur through cyclooxygenase-
independent pathways (12–15). The thienopyridine anti-
platelet agents ticlopidine and clopidogrel specifically inter-
fere with the adenosine diphosphate (ADP)-induced
activation pathway to inhibit ADP-induced platelet activa-
tion (14,15). In clinical studies, a combination of aspirin and
antiplatelet therapy (such as dipyridamole or clopidogrel)
has proven to be of higher benefit than either drug alone in
reducing platelet-induced thrombus formation in a variety
of atherosclerotic vascular disorders, such as ischemic heart
disease and unstable angina (16). Indeed, combination
antiplatelet therapy appears to be superior to warfarin
regimens in reducing stent thrombosis and hemorrhagic
complications (17).
We hypothesized that introducing combination therapy
with aspirin (75 mg) and clopidogrel (75 mg) could reduce
indices of thrombogenesis when compared to dose-adjusted
anticoagulation with warfarin (achieving an INR of 2.0 to
3.0). To test this, we performed a prospective randomized
trial of aspirin-clopidogrel combination therapy versus
adjusted-dose warfarin in nonvalvular AF.
SUBJECTS AND METHODS
We studied 70 outpatients (44 men; mean age 70 [SD 10]
years) with chronic nonvalvular AF who were not receiving
antithrombotic therapy and had been referred to a specialist
outpatient clinic for consideration of anticoagulation over a
12-month period. Chronic AF was confirmed electrocar-
diographically on at least two separate occasions (4 weeks
apart). We excluded any patients with hematological, renal
(creatinine200 mg/dl), hepatic (liver enzymes twice the
upper limit of normal), inflammatory or neoplastic disorders
and those who suffered recent (3 months) myocardial
infarction or stroke, as these disorders might influence
platelet activation and the levels of the markers measured.
Patients who consumed regular nonsteroidal anti-
inflammatory drugs, corticosteroids or hormone replace-
ment therapy were also excluded. Furthermore, patients
with rheumatic mitral valvular disease, prosthetic cardiac
valves and acute AF precipitated by thyrotoxicosis or any
acute infection were excluded from the study. The study was
approved by the City Hospital ethics committee and in-
formed consent was obtained from patients.
We randomized the 70 patients with chronic nonvalvular
AF to either dose-adjusted warfarin (INR 2-3) (Group I, n
 35; 23 men; mean age 69 years, SD 11) or combination
therapy with aspirin 75 mg and clopidogrel 75 mg (Group
II, n 35; 21 men; mean age 71 years, SD 8). Patients were
seen at baseline (visit 1) and then at six weeks (visit 2) after
randomization. The patients randomized to warfarin were
referred to and regularly seen in the hospital anticoagulation
clinic to achieve and maintain an INR of 2.0 to 3.0. Because
of patient withdrawals, complete samples for haemostatic
markers were taken at six-week follow-up visit in only 33
patients in Group I and only 32 patients in Group II; paired
comparisons between baseline and posttreatment samples
were performed on these 33 and 32 patients, respectively.
Baseline blood results in patients with AF were compared
with “healthy controls,” which consisted of 50 normal
subjects (23 men; 70 years, SD 13) recruited from healthy
hospital staff, relatives of the patients and those attending
the hospital for routine senile cataract surgery. The subjects
were nonsmokers with no clinical evidence of vascular,
metabolic, neoplastic or inflammatory disease on careful
history, examination and routine laboratory tests. Clinically,
these subjects were normotensive and in sinus rhythm. The
reason for including this healthy control group was not to
emphasize a case/control comparison (as previously ad-
dressed by many other authors [1]), but to indicate approx-
imate “normal” levels of the hemostasis markers for com-
parisons with the AF patient group.
Laboratory. Blood samples were drawn from an antecubi-
tal vein with atraumatic venipuncture into plastic tubes with
3.2% sodium citrate for platelet aggregation study, and also
for the quantification of plasma indices of thrombogenesis
(fibrin D-dimer, prothrombin fragment 12) and platelet
activation (beta-thromboglobulin [beta-TG] and soluble
P-selectin). Blood for plasma beta-TG levels were collected
in vacutainers containing citrate, theophylline, adenosine
and dipyridamole.
Blood samples for the quantification of plasma markers
were separated within 1 h of collection by centrifugation at
3,000 rpm for 10 min. Aliquots were stored at 70°C to
allow batch analysis. Soluble P-selectin (R and D Systems,
Abington, United Kingdom), beta-TG levels (Asserachrom
beta-TG, Diagnostica Stago, Asnieres Sur Seine, France),
fibrin D-dimer (Technoclone, Wien, Austria) and pro-
thrombin fragment 12 (Enzygnost F 12 micro, Dade
Behring Marburg GmbH, Marburg, Germany) were all
determined by enzyme-linked immunosorbent assay. In-
traassay and interassay coefficients of variation for all
Abbreviations and Acronyms
ADP  adenosine diphosphate
AF  atrial fibrillation
beta-TG  beta-thromboglobulin
INR  international normalized ratio
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enzyme-linked immunosorbent assays were 5% and
10% respectively.
Citrated blood for platelet aggregation was maintained at
room temperature (22°C) until sample preparation to main-
tain platelet activity. Citrated blood tubes were centrifuged
within 1 h of collection, at room temperature at 1,000 rpm
for 10 min. The supernatant platelet-rich plasma was
separated. The residual sample was then centrifuged at
2,000 rpm for 20 min to obtain a clear citrated supernatant,
platelet-free plasma. Ex vivo platelet aggregation was mea-
sured in a plasma platelet aggregometer (Platelet aggrega-
tion profiler, model PAP-4, Bio/Data Corporation, Horsham,
Pennsylvania). Aggregation was induced by the addition of the
following reagents: 1) ADP (final concentration of 0.1 mol/
ml), 2) collagen (final concentration of 2 mg/ml), epinephrine
(final concentration of 0.1 mol/ml) (Sigma Diagnostics, St.
Louis, Missouri) and 3) thrombin (final concentration of 10
NIH U/ml) (Pacific Hemostasis, Huntersville, North Caroli-
na). Platelet aggregation curves were recorded and the extent of
platelet aggregation was evaluated by measuring the percentage
platelet aggregation at the end of 3 min.
Power calculations. We have previously demonstrated that
six weeks of dose-adjusted warfarin reduced median levels of
fibrin D-dimer by 50% among 51 patients with AF (6) and
by 40% in 61 different patients (7). However, in the current
study, because we intended to measure additional indices,
we more conservatively hypothesized a reduction in median
D-dimer levels (due to either intervention) of one-third of
its pretreatment (baseline) level. In order to achieve this
difference at p  0.05 and a 1-beta of 0.8 we needed good
data from 25 subjects per intervention group. However, as
stated, we recruited in excess of this figure to improve our
chances of minimizing Types I and II errors. We compared
our 70 patients at baseline to 50 healthy controls. The
reason for including this latter group is not to provide hard
case/control data but to indicate approximate levels of the
hemostasis markers in the patient group. However, these
numbers provide sufficient power to detect a difference of
0.4 of a standard deviation, under the same probability
conditions, should one be present.
Statistical analysis. Results are expressed as mean, SD or
as median (interquartile range) for the normally distributed
data and nonparametrically distributed data respectively.
Data between patients with AF and healthy controls were
analyzed using the unpaired t test or Mann-Whitney U tests
as appropriate. Paired data, which were comparisons of
baseline levels with those for six weeks posttreatment, were
performed using the paired t test or paired Wilcoxon test, as
appropriate. Correlations were performed using the Spear-
man rank correlation method, and categorical data were
compared with use of the 2 test. All statistical calculations
were performed on a microcomputer using a commercially
available statistical package (Minitab release 12, Minitab
Inc., State College, Pennsylvania). A p value 0.05 was
considered as statistically significant.
RESULTS
Cross-sectional analyses. Clinical characteristics, includ-
ing patient demography of the study population, are shown
in Table 1. Age and gender ratios were similar between AF
patients and controls. Plasma levels of fibrin D-dimer (p 
0.001), beta-TG (p 0.012) and soluble P-selectin levels (p
 0.03) were significantly higher in patients with AF at
baseline when compared with controls (Table 2). Plasma
prothrombin fragment 12 levels and platelet aggregation
in response to various platelet agonists were no different
between healthy controls and patients with AF at baseline
(all p  NS) (Table 2). There were no significant correla-
tions between various indices of thrombogenesis and plate-
let activation, and platelet aggregation in the whole cohort
of AF patients at baseline (Spearman, p  NS; data not
shown).
Patients with AF who were on no antithrombotic therapy
at baseline, and with no associated risk factors such as
hypertension, diabetes mellitus, IHD, cardiac failure or left
ventricular hypertrophy (on electrocardiography) were clas-
sified as having “lone AF” (n  11). These “lone AF”
patients were compared to patients with risk factors (that is,
not lone AF; n  59), the subgroups being comparable in
terms of age and gender distribution (Table 2, B). The
hematological and platelet aggregation parameters were no
different between lone AF and those with risk factors except
for plasma levels of soluble P-selectin, which were higher in
the former subgroup (p  0.01).
Treatment with warfarin (Group I) or aspirin-
clopidogrel combination therapy (Group II). Patients
with AF in two treatment groups were of similar age and
gender ratio (Table 3). The majority of clinical cardiovas-
cular risk factors or underlying diseases did not differ
significantly between the subgroups of patients with AF,
although the AF patients subsequently randomized to
combination antiplatelet therapy had a higher prevalence
of ischemic heart disease (p  0.03), whereas a signifi-
cantly higher proportion of patients randomized to war-
Table 1. Clinical Characteristics of Patients With Atrial
Fibrillation and Healthy Controls in Sinus Rhythm
Healthy
Controls
AF on
No Therapy
(Baseline) p Value
Number of subjects (n) 50 70
Age in years (mean  SD) 70  13 70  10 0.88
Gender ratio (male:female) 23:27 44:26 0.07
Smoker:nonsmoker — 10:60 —
Hypertensive:normotensive — 42:28 —
Diabetics:nondiabetics — 9:61 —
CVA:no CVA — 12:58 —
Cardiac failure:no cardiac failure — 9:61 —
IHD:no IHD — 13:57 —
t test or chi-squared test as appropriate.
AF  atrial fibrillation; CVA  cerebrovascular accident; IHD  ischemic heart
disease.
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farin had a previous history of stroke/transient ischemic
attacks (p  0.01).
Patients randomized to dose-adjusted warfarin (Group I)
had a mean INR of 2.4 (SD 0.6). Dose-adjusted warfarin
significantly reduced plasma levels of fibrin D-dimer (p 
0.001), prothrombin fragment 12 (p  0.001) and
beta-TG levels (p  0.001) significantly at six weeks (Table
4). Plasma soluble P-selectin levels were increased signifi-
cantly at six weeks when compared to baseline (p  0.001).
Platelet aggregation was not significantly different after six
weeks’ treatment when compared to baseline (p  NS,
group 1) (Table 4). At six weeks, there were no significant
correlations between any of the coagulation or platelet
markers with the INR (all p  NS, data not shown).
In Group II, there were no significant changes in plasma
indices of thrombogenesis and platelet activation at six weeks
(Table 5). However, platelet aggregation was significantly
decreased in response to ADP (p  0.001) and epinephrine
(p  0.02), although platelet aggregation was not significantly
different in response to collagen and thrombin (Table 5).
DISCUSSION
Our results confirm some of the previous evidence of a
prothrombotic or hypercoagulable state in AF, which ap-
Table 2. Plasma Indices of Thrombogenesis and Platelet Activation, and Platelet Aggregation in
(A) Patients With Chronic AF at Baseline and Healthy Controls in Sinus Rhythm; and (B)
Patients With Lone AF and Those Who Were “Not Lone AF”
(A) Chronic AF Versus Healthy Controls
Healthy Controls
in Sinus Rhythm
Patients With AF
(at Baseline) p Value
n 50 70
Indices of thrombogenesis
Fibrin D-dimer (ng/ml) 580 (387–1,350) 1,150 (740–1,600) 0.001
Prothrombin fragment 12 (nmol/l) 1.4 (1.2–1.6) 1.4 (1.2–1.7) 0.760
Indices of platelet activation
Beta-TG (IU/ml) 63 (49–89) 87 (59–124) 0.012
Soluble P-selectin (ng/ml) 37  10 40  10 0.030
Platelet count (109/l) 261  67 255  70 0.643
Ex vivo platelet aggregation to (platelet agonist)
ADP 70 (53–79) 64 (50–79) 0.53
Collagen 18 (10–59) 22 (08–56) 0.85
Epinephrine 57 (23–70) 46 (28–60) 0.31
Thrombin 52 (04–84) 60 (20–80) 0.79
(B) Lone AF Versus “Not Lone AF”
Lone AF Not ‘Lone AF’ p Value
n 11 59
Age in years (mean  SD) 69  12 70  09 0.71
M:F 7:4 37:22 0.95
Indices of thrombogenesis
Fibrin D-dimer (ng/ml) 1,200 (730–4,875) 1,110 (725–1,600) 0.61
Prothrombin fragment 12 (nmol/l) 1.2 (1.0–1.5) 1.4 (1.2–1.7) 0.06
Indices of platelet activation
Beta-TG (IU/ml) 107 (63–140) 86 (57–120) 0.18
Soluble P-selectin (ng/ml) 50  10 40  9 0.01
Platelet count (109/l) 240  77 258  69 0.48
Ex vivo platelet aggregation to (platelet agonist)
ADP 68 (58–80) 64 (41–78) 0.51
Collagen 16 (08–40) 25 (10–58) 0.22
Epinephrine 50 (28–68) 45 (28–61) 0.54
Thrombin 70 (00–82) 60 (25–80) 0.96
Values expressed as mean  SD and median (interquartile range) as appropriate. All platelet aggregation values expressed as
median (interquartile range) percentage aggregation at 3 min. Unpaired t test, Mann-Whitney U test or chi-squared test, as
appropriate.
AF  atrial fibrillation; ADP  adenosine diphosphate; TG  thromboglobulin.
Table 3. Clinical Characteristics in Two Treatment Groups of
Patients With Atrial Fibrillation at Baseline
Group I
(Warfarin)
Group II
(Aspirin 
Clopidogrel)
p
Value
Number of subjects (n) 35 35
Age in years (mean  SD) 69  11 71  08 0.40
Gender ratio (male:female) 23:12 21:14 0.62
Smoker:nonsmoker 6:29 4:31 0.50
Hypertensive:normotensive 22:13 21:14 0.81
Diabetics:nondiabetics 5:30 4:31 0.72
CVA:no CVA 10:25 2:33 0.01
IHD:no IHD 3:32 10:25 0.03
Cardiac failure:no cardiac failure 3:32 5:30 0.45
Unpaired t test or chi-squared test, as appropriate.
CVA  cerebrovascular accident; IHD  ischemic heart disease.
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pears to be independent of underlying structural heart
disease or etiology, and may contribute to the risk of stroke
and thromboembolism in AF (1,18–21). For example, in
untreated patients with AF, we have confirmed previous
evidence of increased thrombogenesis and fibrin turnover
(increased fibrin D-dimer), as well as abnormal plasma
indices of platelet activation (plasma beta-TG and soluble
P-selectin levels) (6,21). However, ex vivo platelet aggrega-
tion did not significantly differ between AF patients and
controls, in keeping with some (but not all) of the literature
(11). Although limited by small numbers and power, the
hematological and platelet aggregation parameters were no
different between patients with lone AF and those with risk
factors (except for soluble P-selectin), suggesting that the
findings of the study are probably due to AF itself rather
than any associated vascular disease.
In the present study, dose-adjusted warfarin significantly
reduced plasma levels of fibrin D-dimer and prothrombin
fragments 12 at six weeks, in keeping with a reduction in
thrombogenesis and fibrin turnover. This confirms the
previous similar findings (6,7,19) and is consistent with the
beneficial effects of warfarin in the clinical setting. Warfarin
also reduces plasma beta-TG levels, perhaps reflecting
warfarin’s inhibitory action on the production of thrombin,
which is a potent platelet agonist (6). Therefore, warfarin
possibly exerts its beneficial effect in the reduction of stroke
and thromboembolism by two mechanisms: 1) a reduction
in hypercoagulability and thrombogenesis, related to the
fibrin-rich atrial thrombi and 2) (possibly) a reduction in
platelet activation, resulting in a decrease in platelet-rich
thrombi, associated with atherothrombotic vascular disease
commonly present in patients with AF.
Interestingly, warfarin significantly enhanced plasma lev-
els of soluble P-selectin in patients with AF. However, this
finding needs to be interpreted very cautiously. Soluble
P-selectin is thought to originate from platelets (22,23), and
has been hypothesized to be a new marker of platelet
activation (24). However, whether soluble P-selectin levels
represent platelet activation or simply a destruction of
platelets by the reticulo-endothelial system is not entirely
clear. Except for occasional studies investigating plasma
levels of soluble P-selectin in AF (21), other work examin-
ing the role of platelet activation and its correlation to stroke
in AF have predominantly concentrated on platelet surface
expression of P-selectin, rather than plasma soluble
P-selectin levels per se (25–27). Furthermore, plasma solu-
Table 4. Effect of Dose-Adjusted Warfarin (INR 2.0 to 3.0) on Plasma Indices of
Thrombogenesis and Platelet Activation, and Platelet Aggregation in Atrial Fibrillation
Baseline
At Six Weeks
(INR 2.0–3.0) p Value
Plasma markers
Fibrin D-dimer (ng/ml) 1,200 (850–1,400) 368 (273–660)  0.001
Prothrombin fragment 12 (nmol/l) 1.3 (1.2–1.4) 0.6 (0.5–0.8)  0.001
Beta-TG (IU/ml) 106 (66–130) 80 (58–122)  0.001
Soluble P-selectin (ng/ml) 41  10 51  12  0.001
Ex vivo platelet aggregation to (platelet agonist)
ADP 64 (12–74) 60 (55–72) 0.31
Collagen 28 (08–64) 50 (10–74) 0.43
Epinephrine 47 (29–60) 54 (36–65) 0.40
Thrombin 70 (11–86) 58 (20–85) 0.45
Values expressed as mean  SD and median (interquartile range) as appropriate. All platelet aggregation values expressed as
median (interquartile range) percentage aggregation at 3 min. Paired Wilcoxon test or paired t test, as appropriate.
ADP  adenosine diphosphate; INR  international normalized ratio; TG  thromboglobulin.
Table 5. Effect of Combination Antiplatelet Therapy (Aspirin  Clopidogrel) on Plasma
Indices of Thrombogenesis and Platelet Activation, and Platelet Aggregation in Atrial
Fibrillation
Baseline
At Six Weeks
(Aspirin  Clopidogrel) p Value
Plasma marker
Fibrin D-dimer (ng/ml) 1,100 (595–1,600) 835 (538–1,900) 0.65
Prothrombin fragment 12 (nmol/l) 1.5 (1.3–1.8) 1.5 (1.2–1.6) 0.47
Beta-TG (IU/ml) 72 (57–105) 75 (50–93) 0.55
Soluble P-selectin (ng/ml) 42  11 46  14 0.06
Ex vivo platelet aggregation to (platelet agonist)
ADP 66 (56–80) 41 (13–60)  0.001
Collagen 16 (08–40) 10 (07–32) 0.08
Epinephrine 46 (24–70) 34 (23–50) 0.02
Thrombin 50 (14–75) 43 (00–80) 0.41
Values expressed as mean  SD and median (interquartile range) as appropriate. All platelet aggregation values expressed as
median (interquartile range) percentage aggregation at 3 min. Paired Wilcoxon test or paired t test, as appropriate.
ADP  adenosine diphosphate; TG  thromboglobulin.
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ble P-selectin levels did not correlate with plasma beta-TG
levels in patients with AF, in keeping with our previous
observations (21) and the lack of correlation between plasma
beta-TG and P-selectin expression on platelets (28). How-
ever, given the complexity of platelet activation in AF (8), it
is still possible that warfarin enhances some aspects of
platelet activation while suppressing the others. Further-
more, there is some evidence of warfarin causing platelets to
be hyperaggregable in AF (29).
Clopidogrel selectively and irreversibly inactivates
platelet-ADP receptors and reduces vascular events by 30%
to 35% (30). Previous experimental studies in both animals
and humans and large-scale clinical studies have demon-
strated that a combination of aspirin and clopidogrel results
in a combined inhibition of cyclooxygenase and ADP
effects, and provides marked enhancement of antithrom-
botic efficacy in experimental and clinical studies of patients
with atherosclerotic vascular disorders (15,16,31–33). Aspi-
rin selectively and irreversibly interrupts thromboxane A2
production and decreases thromboembolic events by 20% to
25%; interestingly, aspirin therapy results in a nonsignificant
25% reduction in the markers of thrombogenesis (6,18).
However, platelet aggregation was no different in our
patients with AF when compared with healthy controls in
sinus rhythm, and the effect of combination antiplatelet
therapy on platelet aggregation in our patients with AF
would thus seem to be of limited clinical interest. Further-
more, previous studies have failed to relate platelet aggre-
gation to surrogate markers of thromboembolism, such as
spontaneous echo contrast in AF (34). Although there was
reduction in platelet aggregation response to ADP and
epinephrine with combination antiplatelet therapy, the lat-
ter failed to reduce plasma indices of thrombogenesis and
platelet activation in AF. Our observations confirm previous
observations of only partial inhibition of platelet aggrega-
tion by aspirin (alone) in AF (29) and the inhibition of
platelet aggregation in response to ADP and epinephrine,
but not in response to collagen and thrombin (35). It is
believed that epinephrine results in platelet aggregation
through a thromboxane-mediated pathway, whereas colla-
gen and thrombin mediate their platelet aggregatory effects
through thromboxane-independent pathways (35). Further-
more, clopidogrel is an ADP antagonist (36) and it is
therefore not surprising that in the present study, platelet
aggregation to ADP was reduced by aspirin-clopidogrel
combination therapy. Thus, it appears that although various
aspects of platelet activation may often be intimately linked,
each process can occur independently of the other, depend-
ing upon the stimulus used.
The findings from our study raise two important issues.
First, the consistent clinical benefit of antiplatelet therapy in
atherosclerotic vascular disorders, but not in AF, raises the
question whether the nature of platelet activation in AF
differs from that seen in atherothrombotic vascular disorders
(8,11). Second, the available clinical data and the present
study suggest that even though platelet activation exists in
AF, it is probably the enhanced coagulation rather than
platelet activation that plays an important role in the stroke
and thromboembolic risk of AF.
Study limitations. The main objective of our study was to
study the effects of combination aspirin-clopidogrel anti-
platelet therapy and dose-adjusted warfarin on plasma
indices of thrombogenesis and platelet activation, and plate-
let aggregation. Therefore, we have not made any detailed
attempt at correlating these parameters with the patient’s
clinical, demographic or echocardiographic findings at base-
line, in view of many previous analyses on this topic (1).
Thus, there may be the potential for unmeasured differences
(e.g., comorbidity) between groups that may have affected
the results. However, available evidence already points
towards a lack of a significant relationship between markers
of thrombogenesis and patients’ cardiovascular risk profile
or structural cardiac abnormalities on echocardiography
(1,18,20). The study methods also do not allow inference
regarding the clinical or prognostic value of combination
antiplatelet therapy compared to dose-adjusted warfarin,
which would necessitate a large clinical trial. Furthermore,
whether in vitro or ex vivo platelet activation (as measured
by platelet aggregometry) reflects true in vivo activity (as
reflected by plasma beta-TG and soluble P-selectin levels) is
not exactly known (8,11). Although many workers (includ-
ing our group) have published extensively on soluble
P-selectin as an index of platelet activation, we also recog-
nize that many plasma markers of platelet activation do exist
(11), with some debate over which is the best one. The
possibility also arises that the increase in soluble P-selectin
with warfarin could merely reflect a regression to the mean
or some putative seasonal variation in soluble P-selectin.
In conclusion, we have confirmed previous observations
that AF is associated with enhanced thrombogenesis and
platelet activation. Dose-adjusted warfarin significantly re-
duced thrombogenesis and (at least one aspect of) platelet
activation in AF, consistent with its observed clinical
benefit. However, aspirin-clopidogrel combination therapy
failed to reduce plasma indices of thrombogenesis and
platelet activation in AF, although some aspects of ex vivo
platelet aggregation were altered. Anticoagulation with
warfarin may be superior to combination aspirin-clopidogrel
therapy as thromboprophylaxis in AF.
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